CN101631850B - 增加和转移造血干细胞的方法 - Google Patents

增加和转移造血干细胞的方法 Download PDF

Info

Publication number
CN101631850B
CN101631850B CN2008800077612A CN200880007761A CN101631850B CN 101631850 B CN101631850 B CN 101631850B CN 2008800077612 A CN2008800077612 A CN 2008800077612A CN 200880007761 A CN200880007761 A CN 200880007761A CN 101631850 B CN101631850 B CN 101631850B
Authority
CN
China
Prior art keywords
hours
cells
application
hscs
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800077612A
Other languages
English (en)
Chinese (zh)
Other versions
CN101631850A (zh
Inventor
亚历山大·沙科夫
埃夫格尼亚·斯特罗姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statera Biopharma Inc
Original Assignee
Cleveland Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc filed Critical Cleveland Biolabs Inc
Publication of CN101631850A publication Critical patent/CN101631850A/zh
Application granted granted Critical
Publication of CN101631850B publication Critical patent/CN101631850B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2008800077612A 2007-01-09 2008-01-09 增加和转移造血干细胞的方法 Expired - Fee Related CN101631850B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US88416207P 2007-01-09 2007-01-09
US60/884,162 2007-01-09
US88989307P 2007-02-14 2007-02-14
US60/889,893 2007-02-14
US93856407P 2007-05-17 2007-05-17
US60/938,564 2007-05-17
US1324307P 2007-12-12 2007-12-12
US61/013,243 2007-12-12
PCT/US2008/050644 WO2008086426A2 (en) 2007-01-09 2008-01-09 Methods for increasing and mobilizing hematopoietic stem cells

Publications (2)

Publication Number Publication Date
CN101631850A CN101631850A (zh) 2010-01-20
CN101631850B true CN101631850B (zh) 2013-12-04

Family

ID=39609361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800077612A Expired - Fee Related CN101631850B (zh) 2007-01-09 2008-01-09 增加和转移造血干细胞的方法

Country Status (14)

Country Link
US (3) US20100055077A1 (enExample)
EP (1) EP2115124B1 (enExample)
JP (1) JP5389666B2 (enExample)
KR (1) KR101493474B1 (enExample)
CN (1) CN101631850B (enExample)
BR (1) BRPI0806557A2 (enExample)
CA (1) CA2675032A1 (enExample)
EA (1) EA018983B1 (enExample)
IL (1) IL199766A (enExample)
MX (1) MX2009007391A (enExample)
NZ (2) NZ603805A (enExample)
SG (1) SG177959A1 (enExample)
WO (1) WO2008086426A2 (enExample)
ZA (1) ZA200905378B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008260B2 (en) 2005-06-13 2011-08-30 Cleveland Clinic Foundation Methods of protecting against apoptosis using lipopeptides
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
EP2493295A4 (en) * 2009-10-28 2013-05-08 Ford Henry Health System METHOD FOR MINIMIZING LESIONS DUE TO RADIATION EXPOSURE
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
US20130230580A1 (en) * 2010-09-14 2013-09-05 Paul S. Frenette Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
CA2882853C (en) 2012-04-20 2021-11-23 Vineet Gupta Compounds and methods for regulating integrins
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
JP2016518415A (ja) * 2013-10-21 2016-06-23 アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法
CN104744563B (zh) * 2013-12-27 2019-02-26 中国人民解放军军事医学科学院毒物药物研究所 端基具有亲脂性结构的线性脂肽、其制备方法及用途
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
DE19822820A1 (de) * 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US8008260B2 (en) * 2005-06-13 2011-08-30 Cleveland Clinic Foundation Methods of protecting against apoptosis using lipopeptides
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胡晶等.当归多糖对小鼠外周血造血干细胞动员作用的研究.《中草药》.2006,第37卷(第12期),摘要. *

Also Published As

Publication number Publication date
WO2008086426A3 (en) 2008-12-18
EA200900806A1 (ru) 2010-08-30
SG177959A1 (en) 2012-02-28
MX2009007391A (es) 2009-08-13
NZ603805A (en) 2014-03-28
JP2010515748A (ja) 2010-05-13
IL199766A (en) 2015-01-29
WO2008086426A8 (en) 2009-07-30
AU2008204836A1 (en) 2008-07-17
US20140045747A1 (en) 2014-02-13
CN101631850A (zh) 2010-01-20
WO2008086426A2 (en) 2008-07-17
HK1134835A1 (en) 2010-05-14
EP2115124A4 (en) 2012-05-30
US20100055077A1 (en) 2010-03-04
KR20090108703A (ko) 2009-10-16
BRPI0806557A2 (pt) 2014-04-15
JP5389666B2 (ja) 2014-01-15
EP2115124A2 (en) 2009-11-11
KR101493474B1 (ko) 2015-02-16
NZ578928A (en) 2013-03-28
EP2115124B1 (en) 2016-03-16
EA018983B1 (ru) 2013-12-30
US20150174195A1 (en) 2015-06-25
ZA200905378B (en) 2010-05-26
CA2675032A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
CN101631850A (zh) 增加和转移造血干细胞的方法
EP2566954B2 (en) Immunotherapy using redirected allogeneic cells
RU2747728C2 (ru) Применение размноженных популяций гематопоэтических стволовых клеток/клеток-предшественников
Merluzzi et al. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2.
AU2179392A (en) Method for improving autologous transplantation
EP1030675A2 (en) Treatment of hematologic disorders
BR112020011186A2 (pt) regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
Basser et al. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
JP2023505192A (ja) 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞
US5637323A (en) Method of mobilizing pluripotential hematopoietic stem cells with IL-7
HK1134835B (en) Methods for increasing and mobilizing hematopoietic stem cells
AU2008204836B2 (en) Methods for increasing and mobilizing hematopoietic stem cells
KR20040047749A (ko) 올리고뉴클레오타이드 조성물 및 세포 분화 유도시 이의용도
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP4106488B2 (ja) 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
EP4308694A1 (en) Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
Corbí Pathogen recognition by dendritic cells: Role of C-type lectins
Macintyre et al. Splenic natural cytotoxic activity is enhanced during growth of a murine fibrosarcoma
Safa et al. Salt Augments the Alloimmune Response and Accelerates Allograft Rejection.: Abstract# D2788

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1134835

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1134835

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131204

Termination date: 20170109

CF01 Termination of patent right due to non-payment of annual fee